Respiratory Syncytial Virus
RSV outbreak causes shortage of Sanofi, AZ’s Beyfortus
Shortly after Sanofi and AstraZeneca secured a significant FDA approval for their respiratory syncytial virus (RSV) antibody, Beyfortus, the highly ...
Pfizer’s Abrysvo Secures CDC Endorsement for Infant Protection, Intensifying RSV Vaccine Competition
Despite GSK’s Arexvy pioneering the respiratory syncytial virus (RSV) vaccine landscape earlier this summer, Pfizer has persistently challenged the competition ...
EC Approves Pfizer’s Abrysvo, Only RSV vaccine in EU for adults and infants
Pfizer has just received approval from the European Commission (EC) for its groundbreaking vaccine, Abrysvo. This vaccine, targeting the respiratory ...
GSK lowers short-term hopes for RSV treatment Arexvy but raises 2023 forecast
Great expectations surround GSK’s entry into the respiratory syncytial virus (RSV) vaccine market with their upcoming shot, Arexvy, set to ...
GSK’s Arexvy and Moderna’s mRNA-1345 to lead the race for RSV prevention
The respiratory syncytial virus (RSV) is a common cause of respiratory infections, especially in infants and older adults. It can ...
GSK-Financed Study Shows Global Decline in Adult Immunization Rates
Despite the widespread attention given to COVID-19 vaccines in recent times, there has been a significant decline in the uptake ...
The CDC vaccination committee has scheduled a date in August to consider using Sanofi, Arizona’s Beyfortus RSV antibody
Following its highly anticipated FDA approval on Monday, the respiratory syncytial virus (RSV) antibody developed by Sanofi and AstraZeneca is ...
FDA has approved Beyfortus as a treatment for RSV illness in newborns
Source – Sanofi On July 17, 2023 Sanofi and AstraZeneca received approval from the US Food and Drug Administration (FDA) ...
The first respiratory syncytial virus (RSV) vaccine for elderly people, GSK’s Arexvy, received approval from the Medicines and Healthcare Products Regulatory Agency
Source – GSK GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted ...
CDC panel supports this year’s RSV vaccinations from GSK and Pfizer
If the Centres for Disease Control and Prevention (CDC) heed the counsel of professional advisers, adults in the US 60 ...
FDA Advisory Committee Unanimously Recommends Nirsevimab for Preventing RSV Lower Respiratory Tract Disease in Infants
Source: AstraZeneca The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously, with a 21 to 0 decision, affirming the ...
GSK Secures First Approval for RSV Vaccine in EU
The European Commission has given the green light for GSK’s Arexvy to be used in older adults aged 60 or ...
FDA Grants Approval to ABRYSVO, Pfizer’s Vaccine for Preventing Respiratory Syncytial Virus (RSV) in Elderly Individuals
The FDA, on May 31, 2023, granted approval to ABRYSVO (Respiratory Syncytial Virus Vaccine), Pfizer’s bivalent RSV prefusion F (RSVpreF) ...
